TY  - JOUR
AU  - Goss, Glenwood D
AU  - Felip, Enriqueta
AU  - Cobo, Manuel
AU  - Lu, Shun
AU  - Syrigos, Konstantinos
AU  - Lee, Ki Hyeong
AU  - Göker, Erdem
AU  - Georgoulias, Vassilis
AU  - Li, Wei
AU  - Guclu, Salih
AU  - Isla, Dolores
AU  - Min, Young Joo
AU  - Morabito, Alessandro
AU  - Ardizzoni, Andrea
AU  - Gadgeel, Shirish M
AU  - Fulop, Andrea
AU  - Bühnemann, Claudia
AU  - Gibson, Neil
AU  - Kramer, Nicole
AU  - Solca, Flavio
AU  - Cseh, Agnieszka
AU  - Ehrnrooth, Eva
AU  - Soria, Jean-Charles
PY  - 2018
DO  - 10.1001/jamaoncol.2018.0775
UR  - http://hdl.handle.net/10668/12594
T2  - JAMA oncology
AB  - Treatment choice for lung squamous cell carcinoma could be aided by identifying predictive biomarkers. To assess whether patient outcomes in the LUX-Lung 8 trial were associated with ERBB gene family member aberrations in tumor specimens. Ad hoc...
LA  - en
PB  - American Medical Association
KW  - Afatinib
KW  - Carcinoma, Squamous Cell
KW  - Disease-Free Survival
KW  - Erlotinib Hydrochloride
KW  - Genes, erbB
KW  - Aged
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Protein Kinase Inhibitors
KW  - Treatment Outcome
TI  - Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
TY  - research article
VL  - 4
ER  -